This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy
by Kinjel Shah
Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust global demand for Oncotype DX and increased Cologuard orders are likely to have driven Exact Sciences' (EXAS) Q1 performance.
AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).
Glaxo's (GSK) NDA for Daprodustat Gets Accepted by the FDA
by Zacks Equity Research
Glaxo's (GSK) NDA for daprodustat is based on data from the ASCEND phase III program comprising five studies. All the studies meet their primary efficacy and safety endpoints.
Has Brickell Biotech (BBI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Brickell (BBI) and Eli Lilly (LLY) have performed compared to their sector so far this year.
J&J (JNJ) Beats on Q1 Earnings, Suspends COVID Jab Sales View
by Zacks Equity Research
J&J (JNJ) reports mixed first-quarter results. It beats estimates for earnings but misses the same for sales. It cuts full-year outlook.
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
by Zacks Equity Research
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
by Zacks Equity Research
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.
J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.
Healthcare ETFs Outperform Amid Rising Uncertainties
by Neena Mishra
Investors are seeking refuge in healthcare stocks as inflation and rates rise
Eli Lilly (LLY) Stock Moves -0.88%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $308.96 in the latest trading session, marking a -0.88% move from the prior day.
Top Analyst Reports for Alphabet, Amazon & AbbVie
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Amazon.com, Inc. (AMZN), and AbbVie Inc. (ABBV).
Antibody Treatments for COVD-19 Face Challenges in the U.S.
by Ekta Bagri
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a lack of efficacy against the same.
Biogen (BIIB) Down as Medicare Limits Coverage for Aduhelm
by Zacks Equity Research
Biogen (BIIB) stock declines after Medicare limits coverage for FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in CMS-approved studies.
VIR Stock Down on Another Setback for COVID-19 Antibody
by Zacks Equity Research
VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.
If You Invested $1000 in Eli Lilly 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $292.49 in the latest trading session, marking a +0.37% move from the prior day.
Roche (RHHBY) Actemra Application Receives Priority Review
by Zacks Equity Research
Roche (RHHBY) sBLA is seeking approval for the intravenous formulation of arthritis drug Actemra accepted and granted Priority Review in the United States.
Biogen (BIIB) Plans to Start Aduhelm Confirmatory Study in May
by Zacks Equity Research
Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in May 2022. The estimated completion period of the study is four years.
Adagio's (ADGI) COVID-19 Antibody Meets Goals in Studies
by Zacks Equity Research
The stock price of Adagio (ADGI) surge after it reports positive preliminary data from the phase II/III studies, which evaluate its monoclonal antibody for the prevention and treatment of COVID-19.
ImmunoGen (IMGN) Files BLA for Lead Drug in Ovarian Cancer
by Zacks Equity Research
ImmunoGen (IMGN) seeks accelerated approval from the FDA for its lead candidate, mirvetuximab soravtansine, in previously treated platinum-resistant ovarian cancer. This pushes the stock price up.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $291.66, marking a +0.91% move from the previous day.
Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer
by Zacks Equity Research
Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.